Melanoma Molecular Maps Projects

Padova

Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;


  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);


  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.


Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.



LATEST NEWS
The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.




REFERENCE(S):

"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site


Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |


Melanoma News

A protocol for prospective studies of 25-hydroxyvitamin D, leptin and body mass index in relation to cutaneous melanoma incidence and survival.
Stenehjem JS, Grimsrud TK, Rees JR, Vos L, Babigumira R, Veierød MB, Robsahm TE
BMJ Open. 2017 Jun 21;7(6):e014829.
PMID: 28637727 [PubMed - in process]

Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma.
Gordon D, Hansson J, Eloranta S, Gordon M, Gillgren P, Smedby KE
Int J Cancer. 2017 Jun 20;():.
PMID: 28635084 [PubMed - as supplied by publisher]

Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions.
Farberg AS, Glazer AM, White R, Rigel DS
J Drugs Dermatol. 2017 May 1;16(5):428-431.
PMID: 28628677 [PubMed - in process]

[The Mosan Study Group of Pigmented Tumours facing toward the oligometastatic cutaneous melanoma].
Piérard GE, Piérard-Franchimont C, Delvenne P
Rev Med Liege. 2017 Jun;72(6):308-311.
PMID: 28628288 [PubMed - in process]

PLK-1 Immunoreactivity is Associated with Metastases in Cutaneous Melanoma.
Kaczorowski M, Borowiec T, Donizy P, Pagacz K, Fendler W, Lipinski A, Halon A, Matkowski R
J Cutan Pathol. 2017 Jun 19;():.
PMID: 28626898 [PubMed - as supplied by publisher]


NCBI's Disclaimer and Copyright notice